Heart disease kills more people than any other condition on Earth. Every year, millions die from coronary artery disease, arrhythmias, and other cardiac disorders, many of them preventable with early detection. The problem is that traditional diagnosis methods—angiography, stress tests, imaging—are expensive, time consuming, and sometimes invasive. Doctors need better tools.

Artificial intelligence is beginning to provide them. A sweeping review of nearly 70 studies reveals that machine learning algorithms can predict and classify heart disease with remarkable accuracy, sometimes exceeding 99 percent. The findings suggest that AI could soon become a routine part of how cardiologists identify patients at highest risk, particularly in parts of the world where conventional diagnostic tools are scarce or prohibitively expensive.

The research synthesizes work published between 2018 and 2023, a period when machine learning adoption in medicine exploded. It offers the most comprehensive assessment yet of which computational techniques work best, why some outperform others, and what remains to be done before these systems are ready for widespread clinical use.

Why This Matters Now

Heart disease has become a global emergency. According to the World Health Organization, cardiovascular disease accounts for about 32 percent of deaths worldwide. In some regions, the toll is even steeper. Coronary artery disease alone kills approximately 610,000 Americans annually. In low and middle income countries, where healthcare infrastructure is stretched thin, the burden is rising rapidly as lifestyles shift toward urbanization and reduced physical activity.

Conventional diagnosis relies on a battery of tests. Doctors order electrocardiograms, echocardiograms, chest X rays, CT scans. If results are inconclusive, they may recommend cardiac catheterization or angiography, where a catheter is threaded into arteries to visualize blockages. These procedures are costly, sometimes risky, and not available to everyone who needs them.

Machine learning offers an alternative pathway. Unlike imaging or invasive tests, ML algorithms can analyze electronic health records, medical histories, and routine measurements like blood pressure and cholesterol levels. They process vast amounts of data quickly, identifying hidden patterns humans would miss. Most importantly, they produce predictions from information already being collected, with no additional patient risk.

What the Data Revealed

The review examined studies using text based datasets—electronic health records and medical histories—rather than medical images or ECG signals. Researchers wanted to focus on practical, scalable approaches that could be deployed in resource limited settings without expensive imaging equipment.

The results show a clear hierarchy of performance.

Random Forest, an algorithm that combines predictions from multiple decision trees, emerged as the most popular choice among researchers. About 16 percent of the 68 studies reviewed used Random Forest as their primary classifier. When combined with feature selection techniques—methods that identify the most relevant patient variables—Random Forest achieved accuracy rates of 90 to 95 percent, and in the best cases, as high as 99.7 percent.

Support Vector Machines, or SVM, were used in 13 percent of studies. These algorithms excel at binary classification problems and reported accuracy rates of 92 to 93 percent. K Nearest Neighbors, Decision Trees, Logistic Regression, and Naive Bayes each appeared in roughly 10 to 12 percent of studies, with solid but slightly lower performance.

The trend emerging from recent research is revealing. Instead of relying on a single algorithm, researchers increasingly combine multiple techniques. They layer in feature selection to identify which patient characteristics matter most. They use ensemble methods that vote across different algorithms to make final predictions. They apply cross validation to prevent overfitting. These hybrid approaches consistently outperform standalone models.

One study reported 99 percent accuracy using an ensemble of Logistic Regression and K Nearest Neighbors combined with feature selection and cross validation. Another achieved 100 percent accuracy by pairing Decision Trees with principal component analysis, a statistical technique that reduces data complexity. These results, while impressive, rely on datasets that are relatively small and homogeneous—a limitation researchers acknowledge frankly.

The Shape of Risk

Not all heart diseases are equally dangerous. Coronary artery disease, caused by plaque buildup in arteries that supply the heart, has emerged as the highest risk form. The condition is responsible for the majority of cardiovascular deaths. Statistics paint a sobering picture: in the United Kingdom, about 25,000 people under age 75 die from coronary artery disease annually. In the United States, it accounts for roughly one in four deaths.

Risk factors are well established: smoking, diabetes, high blood pressure, high cholesterol, obesity, sedentary lifestyle, stress, and family history. But predicting who will develop disease, and when, remains difficult without computational help. That is where machine learning steps in.

The review found that researchers most frequently targeted coronary artery disease for prediction studies, validating that this is both the most pressing clinical problem and the most amenable to machine learning approaches. Other disease types—arrhythmias, cardiomyopathy, valvular disease—received less attention but showed similar potential.

Why Some Algorithms Win

Each machine learning technique has distinct strengths. Random Forest is robust to missing data and naturally identifies which features matter most, explaining its popularity. K Nearest Neighbors and Decision Trees are intuitive and simple to implement, making them attractive to clinicians unfamiliar with machine learning. Logistic Regression has long roots in medical statistics and offers interpretability—doctors can understand why the algorithm made a particular prediction.

SVM excels when boundaries between disease and health are complex and nonlinear. It works well with high dimensional data where the number of measurements exceeds the number of patients.

But as studies matured from 2018 through 2023, the field discovered something crucial: combining techniques nearly always beats using them alone. An ensemble approach that merges Random Forest with feature selection, for example, amplified accuracy beyond what either component achieved independently. This insight has catalyzed a methodological shift. The best papers now treat algorithm selection as just one piece of a larger pipeline that includes preprocessing, feature engineering, and validation.

The Gap Between Promise and Practice

Despite impressive accuracy numbers in published studies, significant obstacles remain before these systems see routine clinical deployment.

Dataset size is the first problem. Many studies trained and tested algorithms on fewer than 1,000 patients. Machine learning models trained on small datasets risk learning noise rather than genuine disease patterns. When applied to larger, more diverse populations, accuracy often drops. Real hospitals handle hundreds of thousands of patients with varying genetic backgrounds, comorbidities, and medication histories.

Data distribution compounds this issue. Different researchers split their datasets in different ways—some using 70 to 30 percent splits for training versus testing, others using 80 to 20. These choices, while seemingly minor, produce different accuracy estimates. There is no universal standard, making it difficult to compare results across studies fairly.

Real time data remains scarce. Most algorithms were trained on datasets collected years ago. Patient populations and disease characteristics evolve. An algorithm trained on 2015 data may perform poorly on 2025 patients with different risk profiles and treatment options.

Feature selection and hyperparameter optimization add another layer of complexity. Choosing which patient variables to feed into an algorithm significantly impacts results, yet there is no consensus on the best selection methods. Similarly, fine tuning algorithm parameters—learning rates, tree depths, regularization strengths—requires expertise many clinical settings lack.

Missing data is routine in electronic health records. Patients skip appointments, labs go unreported, histories are incomplete. Most studies note that they spent substantial effort on data preprocessing and imputation before training algorithms, yet real hospital data is messier still.

Moving Toward the Clinic

The path forward requires addressing these gaps systematically. Researchers are already pushing in promising directions.

Ensemble methods appear to offer the most immediate path to improvement. By combining algorithms trained on different subsets of features or populations, ensembles hedge against the idiosyncrasies of any single approach. They provide more robust predictions that generalize better to new patient populations.

Feature selection has become a frontier. Studies from 2022 onward emphasize identifying the most clinically relevant measurements, reducing both computational burden and the risk of overfitting to irrelevant noise. Genetic algorithms, which mimic evolutionary selection, are being tested to automate this process.

Integration with clinical workflow is beginning to happen. Rather than replacing doctors, machine learning systems are being designed as decision support tools. Clinicians provide context about patients' circumstances and preferences. The algorithm provides probabilities. Together, they make better decisions than either could alone.

Real time clinical deployment is starting. Some centers have begun testing machine learning models on live patient data, comparing predictions to actual outcomes. These real world studies are harder to publish than controlled retrospective analyses but infinitely more valuable for understanding what works in practice.

The Question of Data

A persistent underlying question haunts the field: where should training data come from? Many studies use standard datasets like the Cleveland dataset, which has been passed around so many times that algorithms optimized for it may have simply memorized its peculiarities. Fresh datasets from diverse populations are needed but slow to arrive.

Patient privacy adds another constraint. Training machine learning models requires access to detailed medical records, sensitive information that hospitals guard carefully. Synthetic data, generated statistically to mimic real patient populations without revealing identities, is emerging as a possible solution but comes with its own validation challenges.

What Comes Next

The systematic review identifies clear priorities for future work. Larger, more diverse datasets are essential. Training algorithms on hundreds of thousands of patients from different continents and healthcare systems would reveal whether current accuracy rates hold in truly unfamiliar populations.

Real time data integration matters. Algorithms trained on current patient information and tested on data collected years after training would show whether they age gracefully or become obsolete.

Collaboration with clinicians deserves emphasis. The best machine learning models will be those designed with input from cardiologists who understand their workflow, their intuitions, and the factors they find most relevant when deciding whether a patient needs aggressive intervention.

Finally, the field needs transparency. As these algorithms move from research papers into clinical practice, understanding how they reach conclusions becomes ethically essential. A doctor cannot responsibly prescribe preventive medication based on a black box prediction. The next generation of heart disease prediction models must be simultaneously accurate and interpretable.

The Promise Remains Real

Despite these challenges, the fundamental promise remains compelling. Machine learning has demonstrated it can identify heart disease risk from readily available patient information with accuracy matching or exceeding conventional diagnostic approaches. The techniques are becoming more sophisticated. Access to computing power is spreading globally. Electronic health records are becoming the norm even in developing nations.

Within the next decade, a patient visiting their primary care doctor might receive not just a blood pressure reading but a machine learning assessment of their cardiovascular risk, updated continuously as new information arrives. Early interventions could prevent heart attacks that conventional approaches would have missed until it was too late.

That future is not certain, but the evidence suggests it is possible. Machine learning is proving itself a tool worthy of the enormous challenge that heart disease represents.

Credit & Disclaimer: This article is a popular science summary written to make peer-reviewed research accessible to a broad audience. All scientific facts, findings, and conclusions presented here are drawn directly and accurately from the original research paper. Readers are strongly encouraged to consult the full research article for complete data, methodologies, and scientific detail. The article can be accessed through https://doi.org/10.1007/s42979-025-03860-2

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.